New shot targets root cause of stubborn acne

NCT ID NCT04856917

Completed Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new injectable drug called imsidolimab could safely reduce acne breakouts. About 123 teenagers and adults with moderate to severe facial acne received either the drug or a placebo (dummy shot) over 20 weeks. Researchers counted pimples and assessed skin appearance to see if the treatment worked better than the placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Site 10-101

San Antonio, Texas, 78213, United States
Site 10-102

College Station, Texas, 77845, United States
Site 10-103

Austin, Texas, 78759, United States
Site 10-104

Detroit, Michigan, 48202, United States
Site 10-105

Murfreesboro, Tennessee, 37130, United States
Site 10-106

Sherman Oaks, California, 91403, United States
Site 10-107

Tampa, Florida, 33613, United States
Site 10-108

Tampa, Florida, 33607, United States
Site 10-109

New Orleans, Louisiana, 70119, United States
Site 10-110

Portsmouth, New Hampshire, 03801, United States
Site 10-111

Fountain Valley, California, 92708, United States
Site 10-112

New Orleans, Louisiana, 70119, United States
Site 10-113

Sweetwater, Florida, 33172, United States
Site 10-114

Hot Springs, Arkansas, 71913, United States
Site 10-115

Waterloo, Ontario, N2J1C4, Canada

Conditions

Explore the condition pages connected to this study.

ACNE VULGARIS